|Bid||4.3700 x 1400|
|Ask||4.3800 x 3000|
|Day's Range||4.3500 - 4.5000|
|52 Week Range||1.8700 - 9.2900|
|Beta (3Y Monthly)||1.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 11, 2019 - Nov 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
Known for pioneering the first renewably sourced, 100% plant-based squalane, the mega-moisture molecule that keeps skin healthy and hydrated, Biossance first launched in 2015, then followed with its No Compromise® campaign in 2016, underpinning the core of the brand, which bans in excess of 2,000 ingredients deemed to have safety and environmental concerns.
Pomerantz LLP is investigating claims on behalf of investors of Amyris, Inc. (“Amyris” or the “Company”) (NASDAQ: AMRS). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. On this news, Amyris’s stock price fell $1.76 per share, or 29.83%, to close at $4.14 per share on November 14, 2018.
NEW YORK , Sept. 9, 2019 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, continues to investigate whether certain ...
EMERYVILLE, Calif., Sept. 4, 2019 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leader in the development and production of sustainable ingredients for the Flavors & Fragrances, Health & Wellness and Clean Beauty markets, announces the official launch of Pipette today. Since its launch, Biossance has brought the best-performing skincare products to the market and continues to define the industry standard for clean beauty. In response to parents asking for better-performing, safer products for their babies, Amyris conceived Pipette: a new Amyris brand reinventing clean personal care for babies and moms using the fewest possible ingredients from the purest sources.
Amyris will provide an update on the progress and performance of its business during the presentation, which is scheduled for Monday, September 9, at 9:10 a.m. ET. A live webcast of the presentation including slides and a replay will be available on the investor relations section of the company's website at http://investors.amyris.com. Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products.
NEW YORK, Aug. 28, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amyris, Inc. ("Amyris" or "the Company") (AMRS). The investigation concerns whether Amyris and certain of its officers and/or directors have violated federal securities laws. On November 13, 2018, Amyris reported disappointing financial results for the third quarter of 2018, including revenue of $14.9 million compared to $22.5 million in the prior year period, citing the "volatility of the Vitamin E market." On this news, Amyris's stock price fell $1.76 per share, or 29.83%, to close at $4.14 per share on November 14, 2018.
Beyond Meat is just the beginning of a new emerging cohort of innovative companies. These innovators are changing how we feed the planet without consuming more of its resources.
EMERYVILLE, Calif., Aug. 22, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today reported that it has received a standard notice from Nasdaq stating that, as a result of not having timely filed its quarterly report on Form 10-Q for the quarter ended June 30, 2019, and because it remains delinquent in filing its annual report on Form 10-K for the year ended December 31, 2018 and its quarterly report on Form 10-Q for the quarter ended March 31, 2019, it is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The Nasdaq notice has no immediate effect on the listing or trading of Amyris's common stock on the Nasdaq Global Select Market.
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, continues to investigate whether certain directors and officers of Amyris, Inc. (“Amyris” or the “Company”) (AMRS) breached their fiduciary duties to the Company and its shareholders. If you are an Amyris shareholder, you are encouraged to contact attorney Joe Pettigrew toll-free at (844) 818-6982 or at firstname.lastname@example.org. Scott+Scott is investigating whether Amyris and its directors and officers made, or allowed Amyris to make, false and/or misleading statements to the investing public.
Lavvan announced the appointment of Neil Closner as its new chief executive officer on Thursday. Closner left his position as CEO of MedReleaf and will be joining Lavvan's team along with seven other members of MedReleaf’s leadership team, Lavvan said in a press release. The company is collaborating with Amyris (NASDAQ: AMRS) on the development of fermentation-based technology that will add knowledge to the way cannabinoids can be applied within the industry.
LAVVAN Inc. (“LAVVAN”) today announced that Neil Closner, formerly of MedReleaf Corp. ("MedReleaf"), has been appointed its new Chief Executive Officer. Former LAVVAN CEO, Etan Bendheim, will become President of the company. Closner has more than two decades of start-up, technology and health care experience.
EMERYVILLE, Calif., July 26, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS) will host a business update teleconference and webcast on Monday, August 5, 2019 prior to presenting at the Jefferies Global Industrials Conference in New York on August 6, following which the company plans to participate in investor meetings in New York and Boston through August 8. The purpose of the call is to discuss solid progress in the company's business thus far during 2019, provide updates on Amyris's brands, plant construction, debt, and status of working toward achieving filing compliance with the Securities & Exchange Commission. Participants should ask to be joined to the Amyris, Inc. call.
LEÓN, Spain and EMERYVILLE, Calif., July 19, 2019 /PRNewswire/ -- ADL Bionatur Solutions (MAB:ADL), a company specialized in research and development of sustainable health and beauty products, services and industrial fermentation production, announces today the expansion of its existing production agreement with Amyris, Inc. (AMRS). Amyris is a leader in the development and production of pure, sustainable, fermentation-derived ingredients for the Health & Clean Beauty markets.
EMERYVILLE, Calif., July 12, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it plans to participate in the following upcoming investor conference in August 2019. Amyris will provide an update on its business during the presentation. A live webcast of the presentation including slides and a replay will be available on the investor relations section of the company's website at http://investors.amyris.com. Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth.
Bragar Eagel & Squire is investigating certain officers and directors of Inogen, Inc., Health Insurance Innovations, Inc., Amyris, Inc., and Nutanix, Inc. More information about each potential case can be found at the link provided. Bragar Eagel and Squire is investigating certain officers and directors of Inogen following a class action complaint that was filed against Inogen on March 6, 2019.
EMERYVILLE, Calif., June 27, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that television personality, podcaster, comedian and beauty expert to the stars Jonathan Van Ness has joined Biossance as the first celebrity ambassador for the brand. The partnership with Jonathan Van Ness marks a milestone in visibility for the brand to advance its mission to make clean the new standard in beauty. "I love incorporating skincare that helps me feel and look my best, while also coming from ethical and sustainably sourced places," says Jonathan Van Ness. "Since the start of my career in the beauty industry, I have been inspired by companies that blend nature and science to create skincare that helps improve the health of skin and people's knowledge of what the ingredients really do.
This is the first application of BLI's Beacon® platform for microbial strains within synthetic biology. The goal of the collaboration is to implement the Beacon platform to identify and isolate microbial strains that produce the highest quantities of non-therapeutic product.
EMERYVILLE, Calif., June 4, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced the appointment of Kathleen Valiasek, formerly Chief Financial Officer, to Chief Business Officer effective immediately. Valiasek will assume a dedicated role of furthering the company's strategy of collaborating with large, well-funded partners to grow the company's business. Simultaneously, she will continue to oversee the company's financing and investor relations activities.
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amyris, Inc. (“Amyris” or “the Company”) (NASDAQ: AMRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at email@example.com.